Anti-Mouse NKG2D/CD314 Antibody (CX5)

Anti-Mouse NKG2D/CD314 Antibody (CX5) is a rat-derived inhibitory antibody targeting mouse NKG2D/CD314. It can reduce the cytotoxicity of natural killer cells and is used in research on cancer, infection, inflammation, immunology, and metabolic diseases, including colitis and diabetes.

Anti-Mouse NKG2D/CD314 Antibody (CX5) reduces the lysis of leukemic cells by natural killer cells [2].
Anti-Mouse NKG2D/CD314 Antibody (CX5) (10 μg/mL) significantly reduces the cytolytic activity of natural killer cells and reverses the enhanced cytotoxicity against YAC‑1 and Panc02 cells induced by a hypoxic environment [4].

Anti-Mouse NKG2D/CD314 Antibody (CX5) (8 mg/kg, intraperitoneal injection, administered on days 0–5, followed by 3 times per week) combined with CTLA‑4 antibody in a mouse model of islet transplantation in diabetic mice can prolong graft survival time and maintain normal blood glucose [1].
Anti-Mouse NKG2D/CD314 Antibody (CX5) (100 μg, intravenous injection, 1 day before and on the day of transplantation) can reduce the clearance of leukemia cells by NK cells in a mouse model transplanted with MLL/ENL‑HPCs [2].
Anti-Mouse NKG2D/CD314 Antibody (CX5) (200 μg, intraperitoneal injection, twice a week from week 2 to week 4) can alleviate colitis symptoms in SCID mice [3].
Anti-Mouse NKG2D/CD314 Antibody (CX5) (200 μg, intraperitoneal injection, once every 3 days starting from 3 days before tumor cell inoculation) can promote tumor growth in mice with the Panc02 tumor model [4].
Anti-Mouse NKG2D/CD314 Antibody (CX5) (50 μg, intraperitoneal injection, on days 6–10 after LMCV infection) used in combination with GAD65-specific CD4+ T cells can prevent the onset of diabetes induced by lymphocytic choriomeningitis virus (LMCV) in mice [5].

CX5

Mouse

Monoclonal

Unconjugated